In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine
- PMID: 11858908
- DOI: 10.1016/s0732-8893(01)00335-2
In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine
Abstract
A total of 33 Stenotrophomonas maltophilia clinical isolates were tested for their susceptibility to clinafloxacin in comparison with ciprofloxacin, levofloxacin, moxifloxacin, nalidixic acid, norfloxacin, sparfloxacin and trovafloxacin. The MIC(50) and MIC(90) were as follows: ciprofloxacin 4 and 64 microg/mL; clinafoxacin 0.5 and 4 microg/mL; levofloxacin 2 and 32 microg/mL; moxifloxacin 1 and 8 microg/mL; nalidixic acid 8 and 128 microg/mL; norfloxacin 64 and 256 microg/mL; sparfloxacin 1 and 16 microg/mL; and trovafloxacin 1 and 8 microg/mL. Clinafloxacin was the most active quinolone, with only a 15.1% of strains showing resistance. When the MICs were determined in the presence of 25 microg/ml of reserpine, the MIC(90) of trovafloxacin and moxifloxacin did not change, whereas decreased 2-fold for clinafloxacin, levofloxacin, sparfloxacin and nalidixic acid, and 4- and 8-fold for ciprofloxacin and norfloxacin respectively. No clinafloxacin-resistant strains were observed when the MIC was performed in the presence of reserpine. Therefore, clinafloxacin shows the better "in vitro"activity against these 33 strains of S.maltophilia.
Similar articles
-
Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.Antimicrob Agents Chemother. 1999 Sep;43(9):2251-5. doi: 10.1128/AAC.43.9.2251. Antimicrob Agents Chemother. 1999. PMID: 10471574 Free PMC article.
-
Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates.J Antimicrob Chemother. 2002 Mar;49(3):471-7. doi: 10.1093/jac/49.3.471. J Antimicrob Chemother. 2002. PMID: 11864947
-
Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia.Eur J Clin Microbiol Infect Dis. 1999 Dec;18(12):908-11. doi: 10.1007/s100960050430. Eur J Clin Microbiol Infect Dis. 1999. PMID: 10691206
-
A critical review of the fluoroquinolones: focus on respiratory infections.Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002. Drugs. 2002. PMID: 11790155 Review.
-
The fluoroquinolone antibacterials: past, present and future perspectives.Int J Antimicrob Agents. 2000 Sep;16(1):5-15. doi: 10.1016/s0924-8579(00)00192-8. Int J Antimicrob Agents. 2000. PMID: 11185413 Review.
Cited by
-
Fluoroquinolone resistance mechanism of clinical isolates and selected mutants of Pasteurella multocida from bovine respiratory disease in China.J Vet Med Sci. 2014 Dec;76(12):1655-7. doi: 10.1292/jvms.14-0240. Epub 2014 Sep 17. J Vet Med Sci. 2014. PMID: 25649952 Free PMC article.
-
Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis.Ann Clin Microbiol Antimicrob. 2024 Mar 19;23(1):26. doi: 10.1186/s12941-024-00685-4. Ann Clin Microbiol Antimicrob. 2024. PMID: 38504262 Free PMC article.
-
Genomic and phenotypic characterisation of fluoroquinolone resistance mechanisms in Enterobacteriaceae in Durban, South Africa.PLoS One. 2017 Jun 21;12(6):e0178888. doi: 10.1371/journal.pone.0178888. eCollection 2017. PLoS One. 2017. PMID: 28636609 Free PMC article.
-
The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.Clin Microbiol Rev. 2015 Apr;28(2):337-418. doi: 10.1128/CMR.00117-14. Clin Microbiol Rev. 2015. PMID: 25788514 Free PMC article. Review.
-
Unusual and Unconsidered Mechanisms of Bacterial Resilience and Resistance to Quinolones.Life (Basel). 2024 Mar 14;14(3):383. doi: 10.3390/life14030383. Life (Basel). 2024. PMID: 38541707 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources